Skip to main content

Gene Discovery Points to a New Form of Alzheimer's

Medically reviewed by Carmen Pope, BPharm. Last updated on May 7, 2024.

By Dennis Thompson HealthDay Reporter

TUESDAY, May 7, 2024 -- People who carry two copies of the gene mutation most strongly implicated in Alzheimer’s disease are almost certain to develop brain changes related to the degenerative disorder, a new study says.

A single mutated APOE4 gene has been found to pose the strongest genetics-driven risk factor for late-onset Alzheimer’s, researchers said.

Virtually everyone with two copies of the APOE4 gene mutation wound up with higher levels of Alzheimer’s-related brain by age 55, compared to people with another version of APOE, researchers reported May 6 in the journal Nature Medicine.

By age 65, more than 95% of people with two APOE4 genes showed abnormal levels of amyloid protein in their cerebrospinal fluid and 75% had positive amyloid scans, researchers said. Amyloid beta plaques are one of the hallmark symptoms of Alzheimer’s.

These findings suggest that having two copies of the APOE4 gene could represent a new genetic form of Alzheimer’s disease, said Dr. Juan Fortea, director of the Memory Unit at the Sant Pau Research Institute’s Neurology Service in Barcelona, Spain.

“This gene has been known for over 30 years and it was known to be associated with a higher risk of developing Alzheimer's disease. But now we know that virtually all individuals with this duplicated gene develop Alzheimer's biology,” Fortea said in a news release.

“This is important because they represent between 2 and 3% of the population," he added.

For the study, Fortea and colleagues analyzed data from nearly 3,300 brain donors, including samples from 273 people with two copies of the APOE4 gene.

The team also evaluated clinical data from more than 10,000 people with evidence of Alzheimer’s disease, including 519 people with two copies of APOE4.

"The data clearly show that having two copies of the APOE4 gene not only increases the risk, but also anticipates the onset of Alzheimer's, reinforcing the need for specific preventive strategies,” researcher Dr. Alberto Lleó, director of the Sant Pau Research Institute’s Neurology Service, said in a news release.

Because people who test positive for two copies of APOE4 are almost certain to develop Alzheimer’s, they could be the focus of clinical trials aimed at testing targeted prevention and treatment methods, the researchers said.

Sources

  • Sant Pau Research Institute, news release, May 6, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted May 2024

Read this next

Brain Decline, Dementia Common Among Older American Indians

THURSDAY, May 16, 2024 -- Higher rates of blood vessel-damaging conditions like hypertension or diabetes may be driving up rates of cognitive decline and dementia among older...

Stroke, Migraine, Alzheimer's: Climate Change Will Likely Make Them Worse

THURSDAY, May 16, 2024 -- Climate change is likely to make brain conditions like stroke, migraine, Alzheimer’s disease, epilepsy and multiple sclerosis even worse, a new...

Tips to Celebrating Mom on Her Day, Even When Dementia Intervenes

SATURDAY, May 11, 2024 -- Women account for two-thirds of all Americans living with Alzheimer’s disease, which means this Mother’s Day will be bittersweet for many...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.